Title: Platelet-derived growth factor receptor-β gene expression relates to recurrence in colorectal cancer

Author(s): 藤野, 志季

Citation

Issue Date

Text Version: none

URL: http://hdl.handle.net/11094/69428

DOI

rights
論文審査の結果の要旨及び担当者

（申請者氏名） 藤野 志幸

<table>
<thead>
<tr>
<th>氏名</th>
<th>（職）</th>
</tr>
</thead>
<tbody>
<tr>
<td>森 正樹</td>
<td>大阪大学教授</td>
</tr>
<tr>
<td>奥山 秀臣</td>
<td>大阪大学教授</td>
</tr>
<tr>
<td>八村 俊之</td>
<td>人間大学教授</td>
</tr>
</tbody>
</table>

論文審査の結果の要旨

PDGF（血小板由来成長因子受容体）はチロシンキナーゼ関連受容体で2つの異なる受容体（PDGFRαおよびPDGFRβ）を介して細胞応答を活性化させるが、PDGFRの癌病における発現の意義はまだ明らかではない。大腸癌の184症例を対象として、PDGFRの発現、癌病病理学的因子と無再発生存率、全生存率について検討したところ、単変量解析にて、リンパ節転移性（P<0.001）、リンパ管侵襲性（P=0.019）、静脈侵襲性（P=0.003）、PDGFR高発現（P=0.0019）が無再発生存に関して有意な因子であった。PDGFR高発現群は多変量解析においても独立した予後因子であり（P=0.040）、5年無再発生存率は高発現群において不良であった（P=0.011）。また、siRNAを用いてPDGFR遺伝子発現を抑制したところ、大腸癌細胞の増殖能と浸調能の低下が認められた。PDGFRの選択性阻害薬であるクレノラブにても同様に大腸癌細胞の増殖の低下が認められた。以上よりPDGFRが大腸癌において増殖や浸調、転移に関与すること、その阻害剤であるクレノラブが新規治療薬となる可能性を示したため、学位に倹すると考える。
Synopsis of Thesis

氏名

藤野 志孝

論文題名

Platelet-derived growth factor receptor-β gene expression relates to recurrence in colorectal cancer
（血小板由来成長因子受容体β遺伝子の発現は大腸癌の再発に関わる）

論文内容の要旨

Purpose
Multiple receptor tyrosine kinases and their growth factor ligands have recently been reported to play important roles in cancer progression and metastasis. Platelet-derived growth factor receptors (PDGFRs) belong to a family of cell surface type III receptor tyrosine kinases and have been reported to increase proliferation and migration in several malignant tumors. CRC tissue expresses PDGFR-α and PDGFR-β and these factors were shown to stimulate invasion and liver metastasis formation in mice. The current study examined the correlation between PDGFR-β expression in CRC tissues and clinicopathological factors and also examined the possible use of PDGFR inhibitors for the treatment of CRC.

Methods
This study included 194 patients who underwent surgery for CRC. PDGFR-β expression was examined by real-time reverse transcription-polymerase chain reaction and immunohistochemistry, and expression levels were correlated with various clinical parameters. The biological significance was evaluated by knockdown experiments in colorectal cancer cell lines and the specific PDGFR inhibitor crenolanib.

Results
We determined PDGFR-β mRNA expression levels in primary CRC and adjacent normal colorectal mucosa by quantitative RT PCR. There was no significant difference in PDGFR β mRNA expression levels between tumor and normal tissue. The median PDGFR-β/GAPDH mRNA expression ratio in tumor tissue was 3.01 (range, 0.16–105.97). Patients were then divided into high- and low-expression groups according to the median calculated PDGFR-β expression level. PDGFR-β protein staining was observed in the cytoplasm and cellular membrane of cancer cells by immunohistochemistry. The frequency of high PDGFR-β expression was in accord with the results for PDGFR-β mRNA expression. The relationships between the clinicopathological factors and PDGFR-β expression status in the 194 patients are examined, and PDGFR-β expression was not significantly correlated with any of the examined clinicopathological factors. Disease-free survival (DFS) was evaluated in 169 patients with R0 resection. Patients in the high-PDGFR-β expression group had lower disease-free survival (DFS) compared with the low-expression group (P = 0.011). According to univariate analysis, lymph node metastasis (P < 0.001), positive lymphatic invasion (P = 0.019), positive vascular invasion (P = 0.003), and high PDGFR-β expression (P = 0.019) were significantly correlated with DFS (Table III). Multivariate regression analysis indicated that high PDGFR-β expression (P = 0.040), lymph node metastasis (P < 0.001), and vascular invasion (P = 0.010) were independent predictors of DFS. The expression of PDGFR-β gene was evaluated in three CRC cell lines and six primary cultured CRC cells and all cells expressed PDGFR-β. CRC cell lines, HCT116 and DLD1 were subjected to siRNA knockdown. Significant suppression of endogenous PDGFR-β expression by siRNA was confirmed by real-time RT-PCR. To determine the proliferative properties, cells were seeded and cultured. There were significant differences in numbers between wild-type or negative control and PDGFR-β siRNA (P < 0.05) in both CRC cell lines. And to determine the invasive properties, invasiveness assay was performed. There were significant differences in numbers between negative control and PDGFR-β siRNA (P < 0.05) in both CRC cell lines. Crenolanib is a highly selective PDGFR inhibitor, and effect of crenolanib on CRC cell viability was examined. Human CRC cell lines and primary cultured cells were both sensitive to crenolanib, according to proliferation assay, but not PDGFR-α antibody. It suggests that PDGFR-β inhibitor inhibits the proliferation and crenolanib might be a promising new treatment for CRC via inhibition of PDGFR-β.

Conclusions
High PDGFR-β expression in cancer tissue was an independent marker of poor prognosis relating to recurrence in patients with CRC, and PDGFR-β expression was related to tumor malignancy in CRC cells. PDGFR-β may be a useful prognostic indicator and a potential therapeutic target in patients with CRC.